Interactive Effects of PD-L1 Expression in Tumor and Immune Cells on Prognosis of Esophageal Squamous Cell Carcinoma: A One-Center Retrospective Cohort Study
Open Access
- 1 July 2020
- journal article
- research article
- Published by Taylor & Francis in OncoTargets and Therapy
- Vol. ume 13, 6565-6572
Abstract
Purpose: The present study aimed to investigate the prognostic effect of PD-L1 expressing in tumor and immune cells among patients with esophageal squamous cell carcinoma. Patients and Methods: We performed a retrospective cohort study by consecutively recruiting 142 patients. The clinicopathological features and PD-L1 expression on tumor and immune cells were independently evaluated by two pathologists. Results: The median expression rate of PD-L1 was 5% and 30% in tumor and immune cells, respectively. Patients with higher expression of PD-L1 in tumor cells had shorter disease-free and overall survival, and the HRs were 1.52 for relapse (95% CI: 0.88, 2.60) and 1.48 for death (95% CI: 0.82, 2.69). There was no significant association between the PD-L1 expression in immune cells and survival. However, among the patients with PD-L1 expression rate ≤ 30% in immune cells, the high expression rate of PD-L1 in tumor cells was significantly associated with the relapse and death, with HRs of 2.51 (95% CI: 1.25, 5.06) and 3.51 (95% CI: 1.57, 7.85), respectively. Among patients with PD-L1 expression rate > 30% in immune cells, the PD-L1 expression in tumor cells did not show any association with the disease-free and overall survival. Conclusion: Our study demonstrates that the integration of PD-L1 expression in tumor and immune cells could be used to predict the relapse and survival among patients with esophageal squamous cell carcinoma.Keywords
This publication has 27 references indexed in Scilit:
- Prognostic significance of programmed death-1 and programmed death-ligand 1 expression in patients with esophageal squamous cell carcinomaOncotarget, 2016
- The role of PD-L1 in the radiation response and prognosis for esophageal squamous cell carcinoma related to IL-6 and T-cell immunosuppressionOncotarget, 2016
- Esophageal cancer statistics in China, 2011: Estimates based on 177 cancer registriesThoracic Cancer, 2015
- Clinicopathological and prognostic value of programmed death ligand-1 (PD-L1) in renal cell carcinoma: a meta-analysis2015
- PD-1 identifies the patient-specific CD8+ tumor-reactive repertoire infiltrating human tumorsJournal of Clinical Investigation, 2014
- The blockade of immune checkpoints in cancer immunotherapyNature Reviews Cancer, 2012
- Intrinsic and extrinsic control of peripheral T‐cell tolerance by costimulatory molecules of the CD28/ B7 familyImmunological Reviews, 2011
- B7-H1 Overexpression Regulates Epithelial–Mesenchymal Transition and Accelerates Carcinogenesis in SkinCancer Research, 2011
- TLR3-Stimulated Dendritic Cells Up-regulate B7-H1 Expression and Influence the Magnitude of CD8 T Cell Responses to Tumor VaccinationThe Journal of Immunology, 2009
- Cancer immunoediting: from immunosurveillance to tumor escapeNature Immunology, 2002